Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15095467 | 0.81 | — | — | |
| SCHEMBL1356889 | 0.81 | ALDH1A1 (0.38) | ALDH1A1HTTSMN1; SMN2POLBNPC1 | |
| SCHEMBL22263934 | 0.78 | ALDH1A1 (0.49) | ALDH1A1POLBRAB9ALMNAKDM4E | |
| SCHEMBL102611 | 0.78 | SMN1; SMN2 (0.43) | ALDH1A1HTTSMN1; SMN2POLB | |
| SCHEMBL24037757 | 0.78 | SMN1; SMN2 (0.43) | ALDH1A1HTTSMN1; SMN2POLB | |
| SCHEMBL3368002 | 0.77 | POLB (0.42) | ALDH1A1HTTSMN1; SMN2POLBNPC1 | |
| SCHEMBL22263826 | 0.76 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL1409756 | 0.74 | ALDH1A1 (0.41) | ALDH1A1HTTSMN1; SMN2POLBLMNA | |
| SCHEMBL1357180 | 0.74 | CYP3A4 (0.40) | ALDH1A1HTTSMN1; SMN2POLBTSHR | |
| SCHEMBL3363662 | 0.72 | POLB (0.51) | ALDH1A1SMN1; SMN2POLBNPC1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743828-A1 | PHOTOCURABLE AS WELL AS THERMALLY CURABLE COMPOSITIONS SUITABLE FOR LOW TEMPERATURE CURING | BASF SE (DE) | 2026-05-20 | — | — | EP | disclosed |
| WO-2025011754-A1 | PHOTOCURABLE AS WELL AS THERMALLY CURABLE COMPOSITIONS SUITABLE FOR LOW TEMPERATURE CURING | BASF SE (DE) | 2025-01-16 | — | — | WO | disclosed |
| EP-4114825-B1 | OXIME ESTER PHOTOINITIATORS | BASF SE (DE) | 2024-11-20 | — | — | EP | disclosed |
| CN-113316744-B | Oxime ester photoinitiators with special aroyl chromophores | 巴斯夫欧洲公司 | 2024-07-30 | — | — | CN | disclosed |
| US-20230142648-A1 | OXIME ESTER PHOTOINITIATORS | BASF SE (DE) | 2023-05-11 | — | — | US | disclosed |
| CN-115210219-A | Oxime ester photoinitiators | 巴斯夫欧洲公司 | 2022-10-18 | — | — | CN | disclosed |
| US-20220121113-A1 | OXIME ESTER PHOTOINITIATORS HAVING A SPECIAL AROYL CHROMOPHORE | BASF SE (DE) | 2022-04-21 | — | — | US | disclosed |
| EP-3044208-B1 | OXIME ESTER PHOTOINITIATORS | BASF SE (DE) | 2021-12-22 | — | — | EP | disclosed |
| US-10793555-B2 | Oxime ester photoinitiators | BASF SE (DE) | 2020-10-06 | — | — | US | disclosed |
| EP-3186226-B1 | OXIME SULFONATE DERIVATIVES | BASF SE (DE) | 2020-06-17 | — | — | EP | disclosed |
| EP-3019473-A1 | OXIME ESTER PHOTOINITIATORS | BASF SE (DE) | 2016-05-18 | — | — | EP | disclosed |
| US-20160060214-A1 | POLYMERIZABLE COMPOSITION COMPRISING AN OXIME SULFONATE AS THERMAL CURING AGENT | BASF SE (DE) | 2016-03-03 | — | — | US | disclosed |
| WO-2016030790-A1 | OXIME SULFONATE DERIVATIVES | BASF SE (DE) | 2016-03-03 | — | — | WO | disclosed |
| WO-2015004565-A1 | OXIME ESTER PHOTOINITIATORS | BASF SE (DE) | 2015-01-15 | — | — | WO | disclosed |
| EP-2668156-A1 | POLYMERIZABLE COMPOSITION COMPRISING AN OXIME SULFONATE AS THERMAL CURING AGENT | BASF SE (DE) | 2013-12-04 | — | — | EP | disclosed |
| WO-2012101245-A1 | POLYMERIZABLE COMPOSITION COMPRISING AN OXIME SULFONATE AS THERMAL CURING AGENT | BASF SE (DE) | 2012-08-02 | — | — | WO | disclosed |
| US-7713680-B2 | Radiation sensitive resin composition for forming a protective film, method of forming a protective film from the composition, liquid crystal display device and solid-state image sensing device | JSR CORPORATION (JP) | 2010-05-11 | — | — | US | disclosed |
| US-20090169736-A1 | THERMOSETTING RESIN COMPOSITION, METHOD OF FORMING ANTIHALATION FILM OF SOLID-STATE IMAGING DEVICE, ANTIHALATION FILM FOR SOLID-STATE IMAGING DEVICES, AND SOLID-STATE IMAGING DEVICE | JSR CORPORATION (JP) | 2009-07-02 | — | — | US | disclosed |
| US-20080233515-A1 | RADIATION SENSITIVE RESIN COMPOSITION FOR FORMING A PROTECTIVE FILM, METHOD OF FORMING A PROTECTIVE FILM FROM THE COMPOSITION, LIQUID CRYSTAL DISPLAY DEVICE AND SOLID-STATE IMAGE SENSING DEVICE | JSR CORPORATION (JP) | 2008-09-25 | — | — | US | disclosed |
| EP-1972673-A1 | Radiation sensitive resin composition for forming a protective film, method of forming a protective film from the composition, liquid crystal display device and solid-state image sensing device | JSR Corporation (JP) | 2008-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793555-B2 | Oxime ester photoinitiators | NR2E3, OXER1, CBR3 | ALDH1A1 929/4885HTT 4054/4885SMN1; SMN2 3122/4885 |
| US-20160060214-A1 | POLYMERIZABLE COMPOSITION COMPRISING AN OXIME SULFONATE AS THERMAL CURING AGENT | SULT1E1, COX6B1, SULT1A1 | ALDH1A1 776/4885HTT 4063/4885SMN1; SMN2 2191/4885 |
| US-20230142648-A1 | OXIME ESTER PHOTOINITIATORS | OCIAD1, OCIAD2, OXER1 | ALDH1A1 964/4885HTT 3765/4885SMN1; SMN2 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.